Pediatric Neurocysticercosis

Review Article
  • 173 Downloads

Abstract

Neurocysticercosis is the most common helminth infection of nervous system in humans caused by the encysted larvae of Taenia solium. It is a major cause of epilepsy in tropical areas and the most common cause of focal-onset seizures in North Indian children. Children with neurocysticercosis have pleomorphic manifestations depending on the location, number and viability of the cysts and host response. In endemic areas, neurocysticercosis should be clinically suspected in any child with recent-onset seizures, headache or focal motor deficits where there is no other suggestion of an underlying neurological disorder. Diagnosis of neurocysticercosis is essentially based on neuroimaging; visualization of a scolex is diagnostic. Management includes use of cysticidal drugs usually albendazole, which seems to be effective for lesion resolution and seizure remission, use of steroids and anti-epileptic drugs. Single lesions portend good prognosis with resolution of lesions in >60% of the cases within 6 mo and good seizure control. Prognosis is guarded in cysticercus encephalitis, racemose and extraparenchymal neurocysticercosis.

Keywords

Neurocysticercosis Tropical disease Taenia solium Tape-worm Ring-enhancing lesion 

Notes

Contributions

PS: Revision of the draft and final approval of the manuscript; AGS: Drafted the manuscript and reviewed the literature. PS will act as guarantor for this paper.

Compliance with Ethical Standards

Conflict of Interest

None.

Source of Funding

None.

References

  1. 1.
    Relationship between epilepsy and tropical diseases. Commission on tropical diseases of the international league against epilepsy. Epilepsia. 1994;35:89–93.CrossRefGoogle Scholar
  2. 2.
    Singhi P, Ray M, Singhi S, Khandelwal N. Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. J Child Neurol. 2000;15:207–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Ndimubanzi PC, Carabin H, Budke CM, et al. A systematic review of the frequency of neurocyticercosis with a focus on people with epilepsy. PLoS Negl Trop Dis. 2010;4:e870.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    WHO. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for impementation. Switzerland: World Health Organization; 2012.Google Scholar
  5. 5.
    Del Brutto OH, Garcia HH. Neurocysticercosis in nonendemic countries: time for a reappraisal. Neuroepidemiology. 2012;39:145–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Serpa JA, White AC Jr. Neurocysticercosis in the United States. Pathog Glob Health. 2012;106:256–60.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mafojane NA, Appleton CC, Krecek RC, Michael LM, Willingham AL 3rd. The current status of neurocysticercosis in eastern and southern Africa. Acta Trop. 2003;87:25–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Praet N, Speybroeck N, Manzanedo R, et al. The disease burden of Taenia solium cysticercosis in Cameroon. PLoS Negl Trop Dis. 2009;3:e406.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Montano SM, Villaran MV, Ylquimiche L, et al. Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology. 2005;65:229–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Medina MT, Aguilar-Estrada RL, Alvarez A, et al. Reduction in rate of epilepsy from neurocysticercosis by community interventions: the Salama, Honduras study. Epilepsia. 2011;52:1177–85.Google Scholar
  11. 11.
    Fleury A, Hernandez M, Fragoso G, Parkhouse RM, Harrison LJ, Sciutto E. Detection of secreted cysticercal antigen: a useful tool in the diagnosis of inflammatory neurocysticercosis. Trans R Soc Trop Med Hyg. 2003;97:542–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Khurana S, Aggarwal A, Malla N. Prevalence of anti-cysticercus antibodies in slum, rural and urban populations in and around union territory, Chandigarh. Indian J Pathol Microbiol. 2006;49:51–3.PubMedGoogle Scholar
  13. 13.
    Sahu PS, Patro S, Jena PK, Swain SK, Das BK. Imaging and serological-evidence of neurocysticercosis among patients with seizures in Odisha, an unexplored eastern coastal province in India. J Clin Diagn Res. 2015;9:DC06–10.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Cherian A, Syam UK, Sreevidya D, et al. Low seroprevalence of systemic cysticercosis among patients with epilepsy in Kerala--South India. J Infect Public Health. 2014;7:271–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Parija SC, Balamurungan N, Sahu PS, Subbaiah SP. Cysticercus antibodies and antigens in serum from blood donors from Pondicherry, India. Rev Inst Med Trop Sao Paulo. 2005;47:227–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Prasad KN, Prasad A, Gupta RK, et al. Neurocysticercosis in patients with active epilepsy from the pig farming community of Lucknow district, north India. Trans R Soc Trop Med Hyg. 2009;103:144–50.CrossRefPubMedGoogle Scholar
  17. 17.
    Prasad KN, Verma A, Srivastava S, Gupta RK, Pandey CM, Paliwal VK. An epidemiological study of asymptomatic neurocysticercosis in a pig farming community in northern India. Trans R Soc Trop Med Hyg. 2011;105:531–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Singh G, Bawa J, Chinna D, et al. Association between epilepsy and cysticercosis and toxocariasis: a population-based case-control study in a slum in India. Epilepsia. 2012;53:2203–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Singhi P, Singhi S. Neurocysticercosis in children. J Child Neurol. 2004;19:482–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Ito A, Putra MI, Subahar R, et al. Dogs as alternative intermediate hosts of Taenia solium in Papua (Irian Jaya), Indonesia confirmed by highly specific ELISA and immunoblot using native and recombinant antigens and mitochondrial DNA analysis. J Helminthol. 2002;76:311–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Mahanty S, Garcia HH. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog Neurobiol. 2010;91:172–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Alvarez JI, Rivera J, Teale JM. Differential release and phagocytosis of tegument glycoconjugates in neurocysticercosis: implications for immune evasion strategies. PLoS Negl Trop Dis. 2008;2:e218.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Verma A, Prasad KN, Gupta RK, et al. Toll-like receptor 4 polymorphism and its association with symptomatic neurocysticercosis. J Infect Dis. 2010;202:1219–25.CrossRefPubMedGoogle Scholar
  24. 24.
    Cooke JC, Gelman JS, Harper RW. Echocardiologists' role in the deployment of the Amplatzer atrial septal occluder device in adults. J Am Soc Echocardiogr. 2001;14:588–94.CrossRefPubMedGoogle Scholar
  25. 25.
    Rathore C, Thomas B, Kesavadas C, Radhakrishnan K. Calcified neurocysticercosis lesions and hippocampal sclerosis: potential dual pathology? Epilepsia. 2012;53:e60–2.CrossRefPubMedGoogle Scholar
  26. 26.
    Morales NM, Agapejev S, Morales RR, Padula NA, Lima MM. Clinical aspects of neurocysticercosis in children. Pediatr Neurol. 2000;22:287–91.CrossRefPubMedGoogle Scholar
  27. 27.
    Singhi P, Saini AG, Sankhyan N. Amaurosis fugax caused by neurocysticercosis. Pediatr Infect Dis J. 2014;33:427.CrossRefPubMedGoogle Scholar
  28. 28.
    Singhi P. Neurocysticercosis. Ther Adv Neurol Disord. 2011;4:67–81.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Saini AG, Vyas S, Singhi P. Racemose neurocysticercosis. J Infect Public Health. 2017. https://doi.org/10.1016/j.jiph.2016.11.019.
  30. 30.
    Singhi P, Saini AG. Pediatric neurocysticercosis: current challenges and future prospects. Pediatr Health Med Ther. 2016;7:5–16.CrossRefGoogle Scholar
  31. 31.
    Singhi P, Singhi S. Neurocysticercosis in children. Indian J Pediatr. 2009;76:537–45.CrossRefPubMedGoogle Scholar
  32. 32.
    Del Brutto OH, Wadia NH, Dumas M, Cruz M, Tsang VC, Schantz PM. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci. 1996;142:1–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Del Brutto OH. Diagnostic criteria for neurocysticercosis, revisited. Pathog Glob Health. 2012;106:299–304.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Singhi PD, Baranwal AK. Single small enhancing computed tomographic lesion in Indian children--I: evolution of current concepts. J Trop Pediatr. 2001;47:204–7.CrossRefPubMedGoogle Scholar
  35. 35.
    do Amaral LL, Ferreira RM, da Rocha AJ, Ferreira NP. Neurocysticercosis: evaluation with advanced magnetic resonance techniques and atypical forms. Top Magn Reson Imaging. 2005;16:127–44.CrossRefPubMedGoogle Scholar
  36. 36.
    Singhi PD, Baranwal AK. Single small enhancing computed tomographic lesions in indian children--II. Clinical features, pathology, radiology and management. J Trop Pediatr. 2001;47:266–70.CrossRefPubMedGoogle Scholar
  37. 37.
    Pretell EJ, Martinot C Jr, Garcia HH, Alvarado M, Bustos JA, Martinot C. Differential diagnosis between cerebral tuberculosis and neurocysticercosis by magnetic resonance spectroscopy. J Comput Assist Tomogr. 2005;29:112–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Rajshekhar V, Haran RP, Prakash GS, Chandy MJ. Differentiating solitary small cysticercus granulomas and tuberculomas in patients with epilepsy. Clinical and computerized tomographic criteria. J Neurosurg. 1993;78:402–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Atluri SR, Singhi P, Khandelwal N, Malla N. Evaluation of excretory secretory and 10-30 kDa antigens of Taenia solium cysticerci by EITB assay for the diagnosis of neurocysticercosis. Parasite Immunol. 2009;31:151–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Sahu PS, Parija SC, Jayachandran S. Antibody specific to 43kDa excretory-secretory antigenic peptide of Taenia solium metacestode as a potential diagnostic marker in human neurocysticercosis. Acta Trop. 2010;115:257–61.CrossRefPubMedGoogle Scholar
  41. 41.
    Atluri SR, Singhi P, Khandelwal N, Malla N. Neurocysticercosis immunodiagnosis using Taenia solium cysticerci crude soluble extract, excretory secretory and lower molecular mass antigens in serum and urine samples of Indian children. Acta Trop. 2009;110:22–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Sahu PS, Parija S, Kumar D, Jayachandran S, Narayan S. Comparative profile of circulating antigenic peptides in CSF, serum & urine from patients with neurocysticercosis diagnosed by immunoblotting. Parasite Immunol. 2014;36:509–21.CrossRefPubMedGoogle Scholar
  43. 43.
    Wilson M, Bryan RT, Fried JA, et al. Clinical evaluation of the cysticercosis enzyme-linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis. 1991;164:1007–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Mandal J, Singhi PD, Khandelwal N, Malla N. Evaluation of ELISA and dot blots for the serodiagnosis of neurocysticercosis, in children found to have single or multiple enhancing lesions in computerized tomographic scans of the brain. Ann Trop Med Parasitol. 2006;100:39–48.CrossRefPubMedGoogle Scholar
  45. 45.
    Rodriguez S, Dorny P, Tsang VC, et al. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis. 2009;199:1345–52.Google Scholar
  46. 46.
    Noh J, Rodriguez S, Lee YM, et al. Recombinant protein- and synthetic peptide-based immunoblot test for diagnosis of neurocysticercosis. J Clin Microbiol. 2014;52:1429–34.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Garcia HH, Gilman RH, Catacora M, Verastegui M, Gonzalez AE, Tsang VC. Serologic evolution of neurocysticercosis patients after antiparasitic therapy. Cysticercosis working group in Peru. J Infect Dis. 1997;175:486–9.Google Scholar
  48. 48.
    Camargo JA, Bertolucci PH. Quantification of Fas protein in CSF of patients with neurocysticercosis. Arq Neuropsiquiatr. 2012;70:262–6.CrossRefPubMedGoogle Scholar
  49. 49.
    Camargo JA, Bertolucci PH. Quantification of amino acid neurotransmitters in cerebrospinal fluid of patients with neurocysticercosis. Open Neurol J. 2015;9:15–20.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Otte WM, Singla M, Sander JW, Singh G. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology. 2013;80:152–62.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Kaur S, Singhi P, Singhi S, Khandelwal N. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J. 2009;28:403–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the guideline development subcommittee of the American Academy of neurology. Neurology. 2013;80:1424–9.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J. 2003;22:268–72.PubMedGoogle Scholar
  54. 54.
    Garcia HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev. 2002;15:747–56.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Singhi P, Jain V, Khandelwal N. Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. J Child Neurol. 2004;19:323–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Singhi PD, Dinakaran J, Khandelwal N, Singhi SC. One vs. two years of anti-epileptic therapy in children with single small enhancing CT lesions. J Trop Pediatr. 2003;49:274–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Ash A, Okello A, Khamlome B, Inthavong P, Allen J, Thompson RC. Controlling Taenia solium and soil transmitted helminths in a northern Lao PDR village: impact of a triple dose albendazole regime. Acta Trop. 2015; https://doi.org/10.1016/j.actatropica.2015.05.018.
  58. 58.
    O'Neal SE, Moyano LM, Ayvar V, et al. Ring-screening to control endemic transmission of Taenia solium. PLoS Negl Trop Dis. 2014;8:e3125.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Panic G, Duthaler U, Speich B, Keiser J. Repurposing drugs for the treatment and control of helminth infections. Int J Parasitol Drugs Drug Resist. 2014;4:185–200.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Devi R, Jain A, Hurkat P, Jain SK. Dual drug delivery using lactic acid conjugated SLN for effective management of neurocysticercosis. Pharm Res. 2015;32:3137–48.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2017

Authors and Affiliations

  1. 1.Pediatric Neurology and Neurodevelopment UnitMedanta, The MedicityGurgaonIndia
  2. 2.Pediatric Neurology and Neurodevelopment Unit, Department of Pediatrics, Advanced Pediatrics CentrePostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations